journal article·2020-06

An Ultrasound‐Triggered ROS Sustained Supplier Based on Open Source and Reduce Expenditure Strategy for Colon Cancer Therapy

Huijuan Zhang, Fang Cao, Ling Zhu, Lin Hou, Zhenzhong Zhang

ChemNanoMat· Volume 6· Issue 6
Publisher page

Abstract

Abstract The reactive oxygen species (ROS) play a decisive role in sonodynamic therapy (SDT). However, hypoxic microenvironment of tumors and short lifetime of ROS limit the implementation of SDT. In this work, an ultrasound (US)‐triggered ROS sustained supplier based on open source and reduce expenditure strategy was constructed. The mesoporous titanium dioxide nanoparticles (MTN) were used as carriers and sonosensitizers, to load US‐responsive perfluoropentane (PFP) and bleomycin (BLM), a blocking agent to reduce ROS scavenging. Thereafter, nanoparticles were wrapped by red blood cell membrane (RBCm) with TKD modification (TKD@RMPB). Under US irradiation, MTN disintegrated into small TiO2 nanoparticles to release PFP and BLM. PFP effectively supplied O2 to enhance ROS generation. Furthermore, BLM reduced the activity of SOD enzyme so that ROS clearance would decrease. This dual role contributed ROS explosive accumulation in tumor cells. In vitro results showed the ROS level of TKD@RMPB group was 3.62 times that of MTN group. Compared with MTN, the proportion of DNA damage in TKD@RMPB group increased by 2.23 times. Moreover, in vivo results indicated that TKD@RMPB could significantly reduce pulmonary fibrotic lesions caused by BLM, suggesting that TKD@RMPB realized simultaneous chemotherapy and SDT for HT‐29 colon cancer with high efficiency and low toxicity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Sciences Zhengzhou University Zhengzhou China

Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases Henan Province Zhengzhou China

Collaborative Innovation Center of New Drug Research and Safety Evaluation Henan Province Zhengzhou China

Funding

Henan Postdoctoral Research Grant · Key Program for Science and Technology Research in Henan Province · China Postdoctoral Science Foundation Grant · Key Program for Scientific Research of Universities in Henan province

References (39)

Show source-provided references
1. 10.1021/acsnano.8b0099910.1021/acsnano.8b00999 ↗
2. 10.1021/acsnano.8b0089910.1021/acsnano.8b00899 ↗
3. 10.1021/acsnano.7b0822510.1021/acsnano.7b08225 ↗
4. 10.1038/nm.339410.1038/nm.3394 ↗
5. 10.1038/s41568-018-0006-710.1038/s41568-018-0006-7 ↗
6. 10.1016/j.ctrv.2018.02.00410.1016/j.ctrv.2018.02.004 ↗
7. 10.1016/j.semcdb.2017.05.02310.1016/j.semcdb.2017.05.023 ↗
8. 10.1002/adma.20190073010.1002/adma.201900730 ↗
9. 10.1002/adma.20180018010.1002/adma.201800180 ↗
10. Pang X. · ACS Nano · 2019 · 13 · 2427
11. 10.1021/acsami.9b0327010.1021/acsami.9b03270 ↗
12. 10.1021/jacs.6b1184610.1021/jacs.6b11846 ↗
13. 10.1002/adma.20160201210.1002/adma.201602012 ↗
14. 10.1021/ar200018x10.1021/ar200018x ↗
15. 10.1021/cr100288610.1021/cr1002886 ↗
16. 10.1002/adma.20120529210.1002/adma.201205292 ↗
17. 10.1039/C4CS00300D10.1039/C4CS00300D ↗
18. 10.1021/acs.nanolett.6b0254710.1021/acs.nanolett.6b02547 ↗
19. 10.1021/cr500029g10.1021/cr500029g ↗
20. 10.1021/cr400627u10.1021/cr400627u ↗
21. 10.1021/acsnano.7b0521510.1021/acsnano.7b05215 ↗
22. 10.1039/C8NR07188H10.1039/C8NR07188H ↗
23. 10.1016/j.jconrel.2010.10.01210.1016/j.jconrel.2010.10.012 ↗
24. 10.1016/j.ultsonch.2016.02.02610.1016/j.ultsonch.2016.02.026 ↗
25. 10.1016/j.ultsonch.2013.05.00510.1016/j.ultsonch.2013.05.005 ↗
26. 10.1038/ncomms978510.1038/ncomms9785 ↗
27. 10.1021/acsnano.7b0810310.1021/acsnano.7b08103 ↗
28. 10.1002/adma.20150461710.1002/adma.201504617 ↗
29. 10.1021/acs.nanolett.6b0236510.1021/acs.nanolett.6b02365 ↗
30. 10.1002/adma.20110403310.1002/adma.201104033 ↗
31. 10.1038/nrc154710.1038/nrc1547 ↗
32. 10.1002/adma.20170142910.1002/adma.201701429 ↗
33. 10.1002/adma.20130063810.1002/adma.201300638 ↗
34. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
35. 10.1039/C7CC04764A10.1039/C7CC04764A ↗
36. 10.1016/j.ijpharm.2015.12.01310.1016/j.ijpharm.2015.12.013 ↗
37. 10.1016/j.cell.2017.10.00810.1016/j.cell.2017.10.008 ↗
38. 10.1016/j.biomaterials.2016.01.05710.1016/j.biomaterials.2016.01.057 ↗
39. 10.1021/ja211035w10.1021/ja211035w ↗